Gehad Maghraby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gehad Maghraby has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Amin Roshdy Soliman
Cairo University, Egypt
3 shared publications - Ebtesam Fahmy
Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Mona A. Hegazy
Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Rasmia Elgohary
Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Ahmed Fayed
Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Alia Adel Saleh
Psychiatry Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications
Latest Publications
- 28 September 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 845-854
Development of a simplified 3-site ultrasound skin score in systemic sclerosis: a pilot study
- 28 September 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 845-854
Development of a simplified 3-site ultrasound skin score in systemic sclerosis: a pilot study
- Open Access
- 17 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7241
Real-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study
Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.
- 17 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7241
Open AccessReal-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study
Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.
- Open Access
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 20 (1)
Systemic Sclerosis and Abortion: Determining Factors and Clinical Significance in a Multicenter Study
Objective: The aim of this work was to identify disease-related factors associated with a history of spontaneous abortion in adult female patients with systemic sclerosis (SSc), and to further analyze the distinguishing features of SSc patients with recurrent versus single abortion episodes. Materials and Methods: This multicenter case-control study was extracted from a nationwide SSc cohort of 1,080 patients. Ninety-one female adult SSc patients (8.4%) with a history of spontaneous abortion before 20 completed weeks of gestation were compared with 91 age-matched female SSc patients without a history of spontaneous abortion. Clinical characteristics, comorbidities, organ involvement, medications, and laboratory parameters were analyzed. Results: Patients with spontaneous abortion had significantly longer disease duration (6.4±4.7 vs . 4.6±4.2 years; p =0.007), a higher prevalence of comorbidities (29.7% vs . 15.4%; p =0.03), more frequent telangiectasia (28.6% vs . 12.1%; p =0.009) and a higher frequency of mycophenolate mofetil use (29.7% vs . 15.4%; p =0.03) compared with patients without a history of spontaneous abortion. Recurrent spontaneous abortion occurred in 30 patients (33.0%). Compared with those with a single spontaneous abortion, patients with recurrent spontaneous abortion had significantly higher frequencies of Raynaud’s phenomenon ( p p =0.047), hypo-/hyperpigmentation ( p =0.03), cardiovascular involvement ( p =0.046), anti-Scl-70 positivity ( p =0.01), double autoantibody positivity ( p =0.017), and higher serum triglyceride levels ( p =0.006). Discussion: Patients with SSc have a higher risk of spontaneous abortion than the general population; this risk is likely driven by decidual vasculopathy and fibrosis. Factors contributing to spontaneous abortion were variable in previous reports, with hypertension and long disease duration among the most contributing factors. Conclusion: In women with SSc, spontaneous abortion is associated with longer disease duration, telangiectasia, higher serum creatinine levels, the presence of comorbidities, and the use of MMF. Recurrent spontaneous abortion is associated with anti-Scl-70 positivity, double autoantibody positivity, and hypertriglyceridemia.
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 20 (1)
Open AccessSystemic Sclerosis and Abortion: Determining Factors and Clinical Significance in a Multicenter Study
Objective: The aim of this work was to identify disease-related factors associated with a history of spontaneous abortion in adult female patients with systemic sclerosis (SSc), and to further analyze the distinguishing features of SSc patients with recurrent versus single abortion episodes. Materials and Methods: This multicenter case-control study was extracted from a nationwide SSc cohort of 1,080 patients. Ninety-one female adult SSc patients (8.4%) with a history of spontaneous abortion before 20 completed weeks of gestation were compared with 91 age-matched female SSc patients without a history of spontaneous abortion. Clinical characteristics, comorbidities, organ involvement, medications, and laboratory parameters were analyzed. Results: Patients with spontaneous abortion had significantly longer disease duration (6.4±4.7 vs . 4.6±4.2 years; p =0.007), a higher prevalence of comorbidities (29.7% vs . 15.4%; p =0.03), more frequent telangiectasia (28.6% vs . 12.1%; p =0.009) and a higher frequency of mycophenolate mofetil use (29.7% vs . 15.4%; p =0.03) compared with patients without a history of spontaneous abortion. Recurrent spontaneous abortion occurred in 30 patients (33.0%). Compared with those with a single spontaneous abortion, patients with recurrent spontaneous abortion had significantly higher frequencies of Raynaud’s phenomenon ( p p =0.047), hypo-/hyperpigmentation ( p =0.03), cardiovascular involvement ( p =0.046), anti-Scl-70 positivity ( p =0.01), double autoantibody positivity ( p =0.017), and higher serum triglyceride levels ( p =0.006). Discussion: Patients with SSc have a higher risk of spontaneous abortion than the general population; this risk is likely driven by decidual vasculopathy and fibrosis. Factors contributing to spontaneous abortion were variable in previous reports, with hypertension and long disease duration among the most contributing factors. Conclusion: In women with SSc, spontaneous abortion is associated with longer disease duration, telangiectasia, higher serum creatinine levels, the presence of comorbidities, and the use of MMF. Recurrent spontaneous abortion is associated with anti-Scl-70 positivity, double autoantibody positivity, and hypertriglyceridemia.
- Open Access
- 28 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 123
Serum S100 calcium-binding protein P in systemic lupus erythematosus patients with lupus nephritis and thrombotic microangiopathy: a 12-month longitudinal biomarker study
Purpose: Lupus nephritis (LN) complicated by thrombotic microangiopathy (TMA) represents a severe renal phenotype characterized by immune-mediated inflammation and microvascular injury. S100 calcium-binding protein P (S100P) participates in inflammatory and stress-related signaling, providing a biological rationale for evaluating its potential as a circulating biomarker in LN-TMA. Methods: In this single-center longitudinal biomarker study nested within an observational cohort, 100 patients with systemic lupus erythematosus (SLE) and biopsy-confirmed proliferative LN (ISN/RPS class III or IV) with concomitant TMA were evaluated together with 50 age- and sex-matched healthy participants included for baseline biomarker comparison. Serum S100P was measured at baseline and at 6 and 12 months, and longitudinal changes were examined in relation to renal response, conventional laboratory parameters, SLEDAI-2 K, and renal histopathological indices. Results: Baseline serum S100P was markedly higher in patients with LN-TMA than in healthy participants [median 21.3 (IQR 19.1–24.0) versus 0.1 (0.1–1.0) ng/mL; P < 0.001]. Baseline S100P was not significantly associated with SLEDAI-2 K or renal biopsy activity and chronicity indices. At 6 months, partial responders had lower S100P concentrations than nonresponders [8.5 (7.6–9.2) versus 12.4 (8.6–23.2) ng/mL; P = 0.004; AUC = 0.811]. At 12 months, complete responders had substantially lower concentrations than nonresponders [7.5 (6.7–8.4) versus 27.3 (24.3–29.3) ng/mL; P < 0.001; AUC = 0.967]. Longitudinal S100P changes were associated with changes in creatinine, lactate dehydrogenase, C3, and C4. Conclusion: In this single-center LN-TMA cohort, serum S100P was markedly elevated compared with healthy participants and declined substantially among patients achieving renal response. These findings support an association between longitudinal S100P changes and treatment response but do not establish disease specificity or pretreatment predictive value. S100P should therefore be considered a candidate complementary monitoring biomarker requiring validation in larger multicenter cohorts with appropriate disease-control groups.
- 28 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 123
Open AccessSerum S100 calcium-binding protein P in systemic lupus erythematosus patients with lupus nephritis and thrombotic microangiopathy: a 12-month longitudinal biomarker study
Purpose: Lupus nephritis (LN) complicated by thrombotic microangiopathy (TMA) represents a severe renal phenotype characterized by immune-mediated inflammation and microvascular injury. S100 calcium-binding protein P (S100P) participates in inflammatory and stress-related signaling, providing a biological rationale for evaluating its potential as a circulating biomarker in LN-TMA. Methods: In this single-center longitudinal biomarker study nested within an observational cohort, 100 patients with systemic lupus erythematosus (SLE) and biopsy-confirmed proliferative LN (ISN/RPS class III or IV) with concomitant TMA were evaluated together with 50 age- and sex-matched healthy participants included for baseline biomarker comparison. Serum S100P was measured at baseline and at 6 and 12 months, and longitudinal changes were examined in relation to renal response, conventional laboratory parameters, SLEDAI-2 K, and renal histopathological indices. Results: Baseline serum S100P was markedly higher in patients with LN-TMA than in healthy participants [median 21.3 (IQR 19.1–24.0) versus 0.1 (0.1–1.0) ng/mL; P < 0.001]. Baseline S100P was not significantly associated with SLEDAI-2 K or renal biopsy activity and chronicity indices. At 6 months, partial responders had lower S100P concentrations than nonresponders [8.5 (7.6–9.2) versus 12.4 (8.6–23.2) ng/mL; P = 0.004; AUC = 0.811]. At 12 months, complete responders had substantially lower concentrations than nonresponders [7.5 (6.7–8.4) versus 27.3 (24.3–29.3) ng/mL; P < 0.001; AUC = 0.967]. Longitudinal S100P changes were associated with changes in creatinine, lactate dehydrogenase, C3, and C4. Conclusion: In this single-center LN-TMA cohort, serum S100P was markedly elevated compared with healthy participants and declined substantially among patients achieving renal response. These findings support an association between longitudinal S100P changes and treatment response but do not establish disease specificity or pretreatment predictive value. S100P should therefore be considered a candidate complementary monitoring biomarker requiring validation in larger multicenter cohorts with appropriate disease-control groups.
- Open Access
- 18 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 108
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Background: The global prevalence of obesity continues to rise, with 3 billion adults projected to be affected by 2030. Recent advances in anti-obesity pharmacotherapy, particularly incretin-based medications, have transformed obesity management. This consensus provides evidence-based guidelines for the clinical use of incretin-based obesity management medications (OMMs). Methods: This consensus was developed through consensus narrative review and expert panel deliberation, examining current evidence for approved anti-obesity medications and emerging therapies. Literature searches were conducted in PubMed, Embase, and Cochrane databases through April 2026. Evidence quality was categorized according to study design, consistency of findings, and clinical applicability. Results: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/gastric inhibitory polypeptide (GIP) dual agonists demonstrate substantial efficacy, with mean weight loss ranging from 5–10% with liraglutide to 21–26% with tirzepatide across various endpoints. These medications are recommended for individuals with a BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with weight-related comorbidities. Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), while serious complications are rare. Emerging therapies in development show promising efficacy profiles, with some triple agonists achieving > 20% weight loss in Phase 2 trials. Conclusions: Incretin-based OMMs represent an important therapeutic option when combined with lifestyle interventions. Appropriate patient selection, systematic monitoring, and proactive management of adverse events are essential for optimising outcomes. Ongoing research into novel agents, long-term safety data, and cardiovascular outcomes will continue to refine clinical practice. Implementation should be guided by shared decision-making, considering individual patient factors, preferences, and healthcare system resources.
- 18 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 108
Open AccessIncretins beyond weight and hyperglycemia management: a consensus statement by AASD
Background: The global prevalence of obesity continues to rise, with 3 billion adults projected to be affected by 2030. Recent advances in anti-obesity pharmacotherapy, particularly incretin-based medications, have transformed obesity management. This consensus provides evidence-based guidelines for the clinical use of incretin-based obesity management medications (OMMs). Methods: This consensus was developed through consensus narrative review and expert panel deliberation, examining current evidence for approved anti-obesity medications and emerging therapies. Literature searches were conducted in PubMed, Embase, and Cochrane databases through April 2026. Evidence quality was categorized according to study design, consistency of findings, and clinical applicability. Results: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/gastric inhibitory polypeptide (GIP) dual agonists demonstrate substantial efficacy, with mean weight loss ranging from 5–10% with liraglutide to 21–26% with tirzepatide across various endpoints. These medications are recommended for individuals with a BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with weight-related comorbidities. Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), while serious complications are rare. Emerging therapies in development show promising efficacy profiles, with some triple agonists achieving > 20% weight loss in Phase 2 trials. Conclusions: Incretin-based OMMs represent an important therapeutic option when combined with lifestyle interventions. Appropriate patient selection, systematic monitoring, and proactive management of adverse events are essential for optimising outcomes. Ongoing research into novel agents, long-term safety data, and cardiovascular outcomes will continue to refine clinical practice. Implementation should be guided by shared decision-making, considering individual patient factors, preferences, and healthcare system resources.
- Open Access
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 87
Low dose aspirin beyond coronary artery disease: a structured narrative review
Background: During the past decades, several innovations in the antiplatelet field were established; including its role in the primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD), the development of newer efficient and more safe antiplatelet drugs, moreover, evidence has also accrued on its therapeutic potential that may extend beyond cardiovascular applications, with implications for broader population health and nutrition strategies. This possible role of low-dose aspirin (LDA) has changed the future of aspirin use. Objectives: This structured narrative review explores the evolving role of LDA in the different fields of medicine beyond cardiovascular indications, including nephrology/vascular access, endocrinology/metabolic disorders, oncology, obstetrics, neurology, gastroenterology/hepatology, rheumatology, respiratory medicine, geriatrics/polypharmacy, and primary care/health systems. The review will also offer a clinical perspective on aspirin’s mechanism of action beyond the antiplatelet effects, anti-inflammatory pathways, and novel mechanisms. It aims to synthesize current evidence, assess the relevance of aspirin as a low-cost, scalable intervention within diverse populations and critically evaluate recent guideline changes regarding primary prevention. Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus (inception to January 2025) for studies on LDA beyond cardiovascular disease to identify studies, reviews, and guidelines related to LDA use in non- coronary artery disease (non-CAD) populations. Emphasis was placed on epidemiological findings, clinical trials, and public health perspectives that intersect with nutritional status, chronic disease risk, and health equity. Results: Findings highlight the strong recommendations of LDA in reducing preeclampsia risk in high-risk pregnant women. For the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutated stage II-III colon cancer, LDA lowered recurrence risk by nearly 50%. High-risk antiphospholipid syndrome (APS) patients showed significant thrombosis reduction. Many other medical conditions need shared decision making; however, major bleeding risk increased 1.5–2.0-fold, with additional risk of intracranial hemorrhage, particularly in adults > 70 years. Conclusion: LDA holds a promise as a multifaceted agent in preventive health beyond CAD. Its potential applications warrant further investigation, particularly in high-risk groups.
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 87
Open AccessLow dose aspirin beyond coronary artery disease: a structured narrative review
Background: During the past decades, several innovations in the antiplatelet field were established; including its role in the primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD), the development of newer efficient and more safe antiplatelet drugs, moreover, evidence has also accrued on its therapeutic potential that may extend beyond cardiovascular applications, with implications for broader population health and nutrition strategies. This possible role of low-dose aspirin (LDA) has changed the future of aspirin use. Objectives: This structured narrative review explores the evolving role of LDA in the different fields of medicine beyond cardiovascular indications, including nephrology/vascular access, endocrinology/metabolic disorders, oncology, obstetrics, neurology, gastroenterology/hepatology, rheumatology, respiratory medicine, geriatrics/polypharmacy, and primary care/health systems. The review will also offer a clinical perspective on aspirin’s mechanism of action beyond the antiplatelet effects, anti-inflammatory pathways, and novel mechanisms. It aims to synthesize current evidence, assess the relevance of aspirin as a low-cost, scalable intervention within diverse populations and critically evaluate recent guideline changes regarding primary prevention. Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus (inception to January 2025) for studies on LDA beyond cardiovascular disease to identify studies, reviews, and guidelines related to LDA use in non- coronary artery disease (non-CAD) populations. Emphasis was placed on epidemiological findings, clinical trials, and public health perspectives that intersect with nutritional status, chronic disease risk, and health equity. Results: Findings highlight the strong recommendations of LDA in reducing preeclampsia risk in high-risk pregnant women. For the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutated stage II-III colon cancer, LDA lowered recurrence risk by nearly 50%. High-risk antiphospholipid syndrome (APS) patients showed significant thrombosis reduction. Many other medical conditions need shared decision making; however, major bleeding risk increased 1.5–2.0-fold, with additional risk of intracranial hemorrhage, particularly in adults > 70 years. Conclusion: LDA holds a promise as a multifaceted agent in preventive health beyond CAD. Its potential applications warrant further investigation, particularly in high-risk groups.
- Open Access
- 13 April 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 38
Safety considerations and adverse events associated with exercise across medical disciplines
Background: Exercise (Ex) is widely recommended across medical specialties as a core component of disease prevention and management. However, Ex prescription is frequently generalized, with limited consideration of disease-specific contraindications, baseline fitness, comorbidities, and potential adverse effects. This gap increases the risk of overlooked complications, particularly in patients with chronic, multisystem, or advanced disease. Methods: This narrative review synthesizes available evidence on Ex-related adverse effects across cardiovascular, respiratory, renal, hepatic, rheumatic, neurological, psychiatric, and endocrine, and pediatric conditions. Reported complications range from musculoskeletal injury and disease flares to serious events including arrhythmias, myocardial infarction, sudden cardiac death, exercise-induced hypertension, hypoglycemia, rhabdomyolysis, hypoxemia, bronchoconstriction, seizures, and neurovascular symptoms. Special populations including children, transplant recipients, patients with advanced organ failure, and those receiving anticoagulation or psychotropic therapy, exhibit narrower safety margins. Across specialties, adverse outcomes are inconsistently reported, contraindications are poorly defined, and high-risk patient groups are frequently excluded from clinical trials, limiting the generalizability of existing recommendations. Conclusion: Exercise is a powerful therapeutic intervention that requires individualized prescription to maximize benefits and minimize potential risks. Safe implementation depends on structured pre-exercise evaluation, condition-specific risk stratification, recognition of absolute and relative contraindications, appropriate supervision, and ongoing monitoring. A coordinated, multidisciplinary approach and improved communication between physicians and exercise professionals are essential to maximize benefit while minimizing harm. Further research is urgently needed to establish evidence-based, disease-specific exercise safety frameworks.
- 13 April 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 38
Open AccessSafety considerations and adverse events associated with exercise across medical disciplines
Background: Exercise (Ex) is widely recommended across medical specialties as a core component of disease prevention and management. However, Ex prescription is frequently generalized, with limited consideration of disease-specific contraindications, baseline fitness, comorbidities, and potential adverse effects. This gap increases the risk of overlooked complications, particularly in patients with chronic, multisystem, or advanced disease. Methods: This narrative review synthesizes available evidence on Ex-related adverse effects across cardiovascular, respiratory, renal, hepatic, rheumatic, neurological, psychiatric, and endocrine, and pediatric conditions. Reported complications range from musculoskeletal injury and disease flares to serious events including arrhythmias, myocardial infarction, sudden cardiac death, exercise-induced hypertension, hypoglycemia, rhabdomyolysis, hypoxemia, bronchoconstriction, seizures, and neurovascular symptoms. Special populations including children, transplant recipients, patients with advanced organ failure, and those receiving anticoagulation or psychotropic therapy, exhibit narrower safety margins. Across specialties, adverse outcomes are inconsistently reported, contraindications are poorly defined, and high-risk patient groups are frequently excluded from clinical trials, limiting the generalizability of existing recommendations. Conclusion: Exercise is a powerful therapeutic intervention that requires individualized prescription to maximize benefits and minimize potential risks. Safe implementation depends on structured pre-exercise evaluation, condition-specific risk stratification, recognition of absolute and relative contraindications, appropriate supervision, and ongoing monitoring. A coordinated, multidisciplinary approach and improved communication between physicians and exercise professionals are essential to maximize benefit while minimizing harm. Further research is urgently needed to establish evidence-based, disease-specific exercise safety frameworks.
- Open Access
- 25 September 2025
- Published by PAGEPress Publications in Reumatismo
- Vol. 77 (4)
The diagnostic utility of miRNA21 in systemic sclerosis
Objective. Systemic sclerosis (SSc) is a multisystem autoimmune disease of heterogeneous pathogenesis, including vascular, immunologic, genetic, epigenetic, and environmental factors. Progressive fibrosis is the hallmark of SSc. Intense research has been conducted to unveil new tools for early diagnosis and management, thus reducing morbidity and mortality. miR-21 has recently been considered to play an important role in the fibrosis of SSc. The objective of this study was to evaluate miR-21 levels in SSc patients and study its correlation to the extent of skin fibrosis and association with various clinical characteristics. Methods. A total of 25 patients with SSc who fulfilled the American College of Rheumatology/European Alliance of Associations for Rheumatology 2013 classification criteria, as well as 25 controls, were enrolled in a cross-sectional study. The extent of skin fibrosis was evaluated using the modified Rodnan skin score, and disease severity was assessed using the Medsger severity score. The levels of miR-21 were measured by quantitative real-time polymerase chain reaction. The 2-ΔΔCt method was used for analysis. SSc patients affected by diabetes mellitus, hypertension, renal impairment, heart disease, malignancy, other autoimmune diseases, or a history of serious acute infection within 6 weeks were excluded. Results. There was a high statistically significant difference in miR-21 levels between cases and controls (p<0.001). At a cut-off level of 2.55, miR21 could discriminate between SSc patients and controls with sensitivity 92% and specificity 100%. There was no significant correlation between miR-21 levels and the degree of skin fibrosis. There was a significant positive association between miR-21 levels and the presence of arthritis in SSc patients (p=0.007). Conclusions. miR-21 was suggested as a robust diagnostic biomarker in SSc with superiority over the traditionally utilized antibodies. Additionally, due to its association with arthritis, it is supposed to play a proinflammatory role in addition to its pronounced profibrotic effects. Interestingly, the profibrotic miR-21 may not reflect the extent of skin fibrosis.
- 25 September 2025
- Published by PAGEPress Publications in Reumatismo
- Vol. 77 (4)
Open AccessThe diagnostic utility of miRNA21 in systemic sclerosis
Objective. Systemic sclerosis (SSc) is a multisystem autoimmune disease of heterogeneous pathogenesis, including vascular, immunologic, genetic, epigenetic, and environmental factors. Progressive fibrosis is the hallmark of SSc. Intense research has been conducted to unveil new tools for early diagnosis and management, thus reducing morbidity and mortality. miR-21 has recently been considered to play an important role in the fibrosis of SSc. The objective of this study was to evaluate miR-21 levels in SSc patients and study its correlation to the extent of skin fibrosis and association with various clinical characteristics. Methods. A total of 25 patients with SSc who fulfilled the American College of Rheumatology/European Alliance of Associations for Rheumatology 2013 classification criteria, as well as 25 controls, were enrolled in a cross-sectional study. The extent of skin fibrosis was evaluated using the modified Rodnan skin score, and disease severity was assessed using the Medsger severity score. The levels of miR-21 were measured by quantitative real-time polymerase chain reaction. The 2-ΔΔCt method was used for analysis. SSc patients affected by diabetes mellitus, hypertension, renal impairment, heart disease, malignancy, other autoimmune diseases, or a history of serious acute infection within 6 weeks were excluded. Results. There was a high statistically significant difference in miR-21 levels between cases and controls (p<0.001). At a cut-off level of 2.55, miR21 could discriminate between SSc patients and controls with sensitivity 92% and specificity 100%. There was no significant correlation between miR-21 levels and the degree of skin fibrosis. There was a significant positive association between miR-21 levels and the presence of arthritis in SSc patients (p=0.007). Conclusions. miR-21 was suggested as a robust diagnostic biomarker in SSc with superiority over the traditionally utilized antibodies. Additionally, due to its association with arthritis, it is supposed to play a proinflammatory role in addition to its pronounced profibrotic effects. Interestingly, the profibrotic miR-21 may not reflect the extent of skin fibrosis.
- Open Access
- 22 July 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (1) , 55-64
Genetic and epigenetic insights into systemic lupus erythematosus: linking long non-coding RNA growth arrest-specific transcript 5 and interferon signature
Gehad Gamal Maghraby, M.D., F.R.C.P., Manal Abdel-Moneim El-Menyawi, M.D., Hanan A. Abdel Rehiem, M.D., Olfat Gamil Shaker, M.D., Mina M. Habib, M.D., Rasmia Elgohary, M.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0074
- 22 July 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (1) , 55-64
Open AccessGenetic and epigenetic insights into systemic lupus erythematosus: linking long non-coding RNA growth arrest-specific transcript 5 and interferon signature
Gehad Gamal Maghraby, M.D., F.R.C.P., Manal Abdel-Moneim El-Menyawi, M.D., Hanan A. Abdel Rehiem, M.D., Olfat Gamil Shaker, M.D., Mina M. Habib, M.D., Rasmia Elgohary, M.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0074
- Open Access
- 2 June 2025
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 37 (1) , 1-5
Vomiting as the storyteller in superior mesenteric artery syndrome
Background: Superior mesenteric artery syndrome (SMA) is a rare and underrecognized cause of proximal small intestinal obstruction resulting from compression of the third part of the duodenum between abdominal aorta and superior mesenteric artery. The classic presentation entails postprandial abdominal pain that is relieved in specific postures, early satiety, vomiting and weight loss. However, atypical presentations may lead to delayed diagnosis and management. Case presentation: We report a case of a 28-year-old female who presented with interactable vomiting and progressive weight loss over a two-year period, without associated abdominal pain. Symptoms began during the first trimester of her second pregnancy and persisted despite termination and medical management. She experienced profound hypokalemia, fatigue and oligomenorrhea. Over time, she lost about 30 kg and was complicated with hypothalamic-pituitary axis suppression. Laboratory and ophthalmological work-up ruled out endocrinal, infectious, neurological causes of vomiting. The upper endoscopy revealed pangastritis and duodenitis, while gadolinium-enhanced brain MRI excluded pituitary pathology. Contrast-enhanced CT abdomen demonstrated a narrowed aortomesenteric angle (19.7 degree) and reduced aortomesenteric distance (5 mm), consistent with SMA. The patient failed to respond to conservative measures including nutritional support, electrolyte correction and anti-emetics. She subsequently underwent laparoscopic duodenojejunostomy. Postoperatively, there was marked improvement in her condition regarding resolution of vomiting, weight gain reaching about 60 kg and normalization of hormonal profile. Conclusion: This case underscores the need for heightened clinical suspicion for SMA syndrome in patients with chronic vomiting and weight loss, even in the absence of abdominal pain. Furthermore, hypothalamic-pituitary axis suppression can occur as a rare complication of chronic SMA. Proper clinical, laboratory and radiological assessment should be done for patients diagnosed with SMA to exclude underlying serious illness. Contrast-enhanced CT remains the imaging modality of choice for diagnosis. Early diagnosis is essential for favorable outcomes.
- 2 June 2025
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 37 (1) , 1-5
Open AccessVomiting as the storyteller in superior mesenteric artery syndrome
Background: Superior mesenteric artery syndrome (SMA) is a rare and underrecognized cause of proximal small intestinal obstruction resulting from compression of the third part of the duodenum between abdominal aorta and superior mesenteric artery. The classic presentation entails postprandial abdominal pain that is relieved in specific postures, early satiety, vomiting and weight loss. However, atypical presentations may lead to delayed diagnosis and management. Case presentation: We report a case of a 28-year-old female who presented with interactable vomiting and progressive weight loss over a two-year period, without associated abdominal pain. Symptoms began during the first trimester of her second pregnancy and persisted despite termination and medical management. She experienced profound hypokalemia, fatigue and oligomenorrhea. Over time, she lost about 30 kg and was complicated with hypothalamic-pituitary axis suppression. Laboratory and ophthalmological work-up ruled out endocrinal, infectious, neurological causes of vomiting. The upper endoscopy revealed pangastritis and duodenitis, while gadolinium-enhanced brain MRI excluded pituitary pathology. Contrast-enhanced CT abdomen demonstrated a narrowed aortomesenteric angle (19.7 degree) and reduced aortomesenteric distance (5 mm), consistent with SMA. The patient failed to respond to conservative measures including nutritional support, electrolyte correction and anti-emetics. She subsequently underwent laparoscopic duodenojejunostomy. Postoperatively, there was marked improvement in her condition regarding resolution of vomiting, weight gain reaching about 60 kg and normalization of hormonal profile. Conclusion: This case underscores the need for heightened clinical suspicion for SMA syndrome in patients with chronic vomiting and weight loss, even in the absence of abdominal pain. Furthermore, hypothalamic-pituitary axis suppression can occur as a rare complication of chronic SMA. Proper clinical, laboratory and radiological assessment should be done for patients diagnosed with SMA to exclude underlying serious illness. Contrast-enhanced CT remains the imaging modality of choice for diagnosis. Early diagnosis is essential for favorable outcomes.